| Literature DB >> 26938545 |
Hye Ah Lee1, Su Hyun Park2, Young Sun Hong3, Eun Hee Ha4, Hyesook Park5.
Abstract
Previous evidence suggests the potential for adverse effects of persistent organic pollutants (POPs) on metabolic health even at low-dose exposure levels common among the general population, but there is less evidence of these associations among children. Therefore, as part of a prospective cohort study, 214 children were measured for POPs exposure. After the 1-year follow-up, we assessed the effect of circulating POPs exposure among 158 children aged 7-9 years (at baseline) on the change of metabolic components of metabolic syndrome using multiple regression analysis. In addition, we calculated the continuous metabolic syndrome (cMetS) score and assessed the variation among individuals by POPs exposure. The concentrations of marker polychlorinated biphenyls (PCBs) were significantly associated with increased change in diastolic blood pressure (BP) and triglyceride levels during a 1-year follow-up, after controlling for sex, age, household income, and change in body mass index. Total PCBs also showed a marginal association with increasing cMetS score from the baseline. Of the metabolic components, change in diastolic BP over time showed a notable association with specific PCBs, but no association with organochlorine pesticides. Here, we found that low-dose exposures to PCBs among children in the general population could negatively influence metabolic health, particularly diastolic BP. Increased disease sensitivity during childhood can continue to adulthood, thus, these results support the need for continuous assessment of the health impact of POPs.Entities:
Keywords: children; cohort study; metabolic syndrome; persistent organic pollutants
Mesh:
Substances:
Year: 2016 PMID: 26938545 PMCID: PMC4808933 DOI: 10.3390/ijerph13030270
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Descriptive analysis of concentrations of circulating persistent organic pollutants in children aged 7 to 9 years at baseline (N = 214).
| Persistent Organic Pollutants | Detection Rate (%) | Lipid Adjusted Concentration (ng/g Lipid) | Wet-Weight Concentration (pg/mL) | ||||
|---|---|---|---|---|---|---|---|
| Median | 25th Percentile | 75th Percentile | Median | 25th Percentile | 75th Percentile | ||
| PCB 52 | 92.52 | 2.54 | 1.50 | 3.53 | 15.08 | 8.70 | 19.61 |
| PCB 101 | 89.72 | 1.15 | 0.76 | 1.58 | 6.53 | 4.79 | 8.98 |
| PCB 118 | 96.26 | 1.56 | 1.07 | 2.12 | 8.95 | 6.27 | 11.49 |
| PCB 138 | 99.07 | 2.32 | 1.60 | 3.61 | 13.30 | 9.48 | 21.02 |
| PCB 153 | 99.07 | 4.27 | 2.70 | 7.49 | 24.27 | 15.92 | 41.43 |
| PCB 156 | 73.83 | 0.57 | 0.21 | 0.98 | 3.30 | 0.21 | 5.62 |
| PCB 180 | 98.13 | 2.56 | 1.65 | 4.90 | 16.27 | 10.10 | 29.98 |
| Σ PCB | 24.63 | 14.58 | 35.29 | 143.47 | 91.11 | 208.81 | |
| Marker PCB | 16.78 | 10.41 | 24.41 | 94.10 | 63.49 | 137.97 | |
| Dioxin-like PCB | 3.01 | 1.64 | 4.60 | 17.54 | 10.08 | 26.99 | |
| HCB | 70.09 | 5.65 | 0.60 | 18.58 | 33.10 | 0.60 | 103.82 |
| 61.68 | 1.19 | 0.64 | 2.05 | 6.56 | 0.64 | 11.53 | |
| β-HCH | 96.26 | 6.13 | 3.80 | 11.19 | 36.30 | 21.81 | 62.40 |
| 99.07 | 3.03 | 2.31 | 4.04 | 17.65 | 13.49 | 23.61 | |
| 99.53 | 43.46 | 26.74 | 71.24 | 249.61 | 159.82 | 406.75 | |
PCB, polychlorinated biphenyl; HCB, hexachlorobenzene; β-HCH, β-hexachlorocyclohexane; p,p’-DDT, p,p’-dichlorodiphenyltrichloroethane; p,p’-DDE, p,p’-dichlorodiphenyldichloroethylene; Results below the limit of detection (LOD) were imputed using the equation: LOD/√2. ΣPCB indicates the sum of the levels of all 32 PCB congeners. Marker PCB indicates the sum of the levels of PCBs 28, 52, 101, 138, 153, and 180. Dioxin-like PCB indicates the sum of the levels of PCBs 77, 81, 114, 105, 118, 126, 123, 156, 157, 169, 167, and 189.
Variation in change in metabolic components and continuous metabolic syndrome score during the 1-year follow-up.
| Outcomes | Mean | SD | 95% CI | Correlation | ||
|---|---|---|---|---|---|---|
| Lower | Upper | |||||
| cMetS a | −0.32 | 2.90 | −0.72 | 0.08 | 0.62 | <0.0001 |
| ∆ cMetS | 0.082 | 2.45 | −0.30 | 0.47 | ||
| BMI (kg/m2) a | 16.75 | 2.48 | 16.41 | 17.09 | 0.93 | <0.0001 |
| Relative change of BMI (%) | 4.78 | 5.63 | 3.90 | 5.66 | ||
| Fasting Glucose (mg/dL) a | 79.48 | 7.82 | 78.42 | 80.55 | 0.30 | 0.0001 |
| Relative change of glucose (%) | 2.05 | 13.16 | −0.03 | 4.12 | ||
| HDL-c (mg/dL) a | 61.44 | 11.66 | 59.85 | 63.03 | 0.75 | <0.0001 |
| Relative change of HDL-c (%) | −3.06 | 13.27 | −5.15 | −0.97 | ||
| TG (mg/dL) a | 57.99 | 53.97 | 62.31 | 0.39 | <0.0001 | |
| Relative change of TG (%) | 3.84 | 14.15 | 1.61 | 6.07 | ||
| MAP (mmHg) a | 73.69 | 7.07 | 72.72 | 74.66 | 0.60 | <0.0001 |
| Relative change of MAP (%) | 4.97 | 9.75 | 3.44 | 6.50 | ||
| SBP (mmHg) a | 100.83 | 9.12 | 99.59 | 102.08 | 0.57 | <0.0001 |
| Relative change of SBP (%) | 3.66 | 10.12 | 2.07 | 5.25 | ||
| DBP (mmHg) a | 60.12 | 8.32 | 58.98 | 61.25 | 0.50 | <0.0001 |
| Relative change of DBP (%) | 6.43 | 14.08 | 4.22 | 8.64 | ||
cMetS, continuous metabolic syndrome; BMI, body mass index; HDL-c, high-density lipoprotein cholesterol; TG, triglyceride; MAP, mean arterial blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; SD, standard deviation; 95% CI, 95% confidence interval. Triglyceride values did not follow a normal distribution and so were analyzed as natural log transformed values, with results presented as back-transformed values. a Results at baseline (N = 214); the variation results were estimated from 158 children who participated during the 1-year follow-up. Correlation coefficients for repeated measures of metabolic components were obtained from the Pearson correlation. Mean arterial blood pressure (MAP) was calculated as: [(systolic BP − diastolic BP)/3] + diastolic BP. Relative change (%) was calculated as: (values at follow-up − values at baseline)/values at baseline × 100. Continuous metabolic syndrome (cMetS) score was evaluated as difference (∆) over time.
The effect of circulating lipid-adjusted persistent organic pollutants (natural logarithms value) on the change in metabolic components and continuous metabolic syndrome score over 1-year follow-up, controlling for baseline body mass index.
| Persistent Organic Pollutants | ∆ cMetS Score | Relative Change of BMI (%) | Relative Change of Glucose (%) | Relative Change of HDL−c (%) | Relative Change of TG (%) | Relative Change of SBP (%) | Relative Change of DBP (%) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 95% CI | 95% CI | 95% CI | 95% CI | 95% CI | 95% CI | 95% CI | |||||||||||||||
| PCB 52 | 0.03 | −1.03 | 1.10 | 1.83 | −0.54 | 4.21 | −0.30 | −2.84 | 2.23 | 2.53 | −0.07 | 5.14 | 0.44 | −1.46 | 2.35 | 2.09 | −0.53 | 4.70 | |||
| PCB 101 | 0.38 | −0.06 | 0.82 | −0.01 | −1.04 | 1.02 | −0.20 | −2.52 | 2.12 | 0.02 | −2.43 | 2.47 | 1.41 | −1.13 | 3.96 | 0.07 | −1.77 | 1.92 | 0.88 | −1.67 | 3.42 |
| PCB 118 | 0.36 | −0.36 | 1.09 | −0.29 | −1.84 | 1.27 | 0.33 | −3.44 | 4.09 | −0.57 | −4.56 | 3.42 | 0.75 | −3.40 | 4.90 | −0.12 | −3.12 | 2.87 | 3.56 | −0.55 | 7.66 |
| PCB 138 | 0.24 | −0.28 | 0.76 | 0.14 | −1.02 | 1.29 | −0.98 | −3.69 | 1.74 | −0.55 | −3.42 | 2.33 | −0.04 | −3.04 | 2.95 | 0.72 | −1.42 | 2.87 | |||
| PCB 153 | 0.03 | −0.36 | 0.42 | −0.22 | −1.09 | 0.64 | −0.10 | −2.12 | 1.93 | 0.65 | −1.49 | 2.79 | −0.44 | −2.67 | 1.79 | 0.87 | −0.73 | 2.48 | |||
| PCB 156 | 0.17 | −0.40 | 0.73 | 0.22 | −1.05 | 1.50 | −2.20 | −5.13 | 0.72 | −2.39 | 5.49 | 0.70 | 0.12 | −3.12 | 3.37 | 1.50 | −0.83 | 3.82 | 3.02 | −0.18 | 6.21 |
| PCB 180 | 0.14 | −0.27 | 0.56 | −0.13 | −1.05 | 0.79 | 0.75 | −1.40 | 2.90 | −0.88 | −3.15 | 1.39 | 0.81 | −1.56 | 3.18 | 1.35 | −0.35 | 3.05 | 2.27 | −0.07 | 4.61 |
| ΣPCB | 0.49 | −0.22 | 1.19 | 0.39 | −1.16 | 1.94 | −1.58 | −5.20 | 2.04 | −1.77 | −5.70 | 2.17 | 2.93 | −1.13 | 6.99 | 1.33 | −1.61 | 4.26 | |||
| Marker PCB | 0.39 | −0.28 | 1.06 | 0.30 | −1.18 | 1.79 | −1.70 | −5.14 | 1.75 | −1.08 | −4.83 | 2.66 | 3.04 | −0.81 | 6.90 | 1.65 | −1.14 | 4.44 | |||
| Dioxin-like PCB | −0.08 | −0.73 | 0.57 | −0.03 | −1.45 | 1.40 | −1.30 | −4.90 | 2.31 | −0.09 | −3.83 | 3.65 | 0.66 | −2.03 | 3.35 | 3.44 | −0.23 | 7.11 | |||
| HCB | 0.09 | −0.15 | 0.34 | 0.07 | −0.48 | 0.62 | 0.31 | −1.05 | 1.68 | 0.84 | −0.57 | 2.26 | 0.17 | −0.86 | 1.20 | 0.59 | −0.83 | 2.01 | |||
| −0.19 | −0.75 | 0.37 | 0.35 | −0.88 | 1.58 | −1.46 | −4.38 | 1.47 | 0.76 | −2.34 | 3.87 | −0.58 | −3.81 | 2.65 | −0.29 | −2.61 | 2.03 | 2.21 | −0.98 | 5.39 | |
| β-HCH | −0.26 | −0.59 | 0.08 | −0.50 | −1.26 | 0.27 | 0.43 | −1.34 | 2.20 | 1.85 | 0.00 | 3.70 | −1.66 | −3.59 | 0.27 | 0.00 | −1.41 | 1.41 | 1.04 | −0.89 | 2.98 |
| −0.26 | −0.91 | 0.40 | −0.83 | −2.27 | 0.61 | 0.74 | −2.67 | 4.14 | 1.84 | −1.75 | 5.43 | −1.64 | −5.38 | 2.11 | −0.59 | −3.30 | 2.12 | 1.83 | −1.91 | 5.57 | |
| −0.17 | −0.58 | 0.24 | −0.51 | −1.42 | 0.41 | 0.64 | −1.50 | 2.77 | 1.91 | −0.33 | 4.16 | −1.65 | −4.00 | 0.69 | 0.08 | −1.62 | 1.78 | 1.71 | −0.63 | 4.04 | |
a p < 0.05; cMetS, continuous metabolic syndrome; BMI, body mass index; HDL-c, high-density lipoprotein cholesterol; TG, triglyceride; SBP, systolic blood pressure; DBP, diastolic blood pressure; PCB, polychlorinated biphenyl; HCB, hexachlorobenzene; β-HCH, β-hexachlorocyclohexane; p,p’-DDT, p,p’-dichlorodiphenyltrichloroethane; p,p’-DDE, p,p’-dichlorodiphenyldichloroethylene. Results below the limit of detection (LOD) were imputed using the equation: LOD/√2. Multiple regression models are adjusted for sex, age (months), household income, and BMI at baseline. The regression model for change in BMI is adjusted for sex, age (months), and household income. Relative change (%) in the metabolic components was calculated as: (values at follow-up − values at baseline) / values at baseline × 100. Continuous metabolic syndrome (cMetS) score was evaluated as difference (∆) over time. ΣPCB indicates the sum of the levels of all 32 PCB congeners. Marker PCB indicates the sum of the levels of PCBs 28, 52, 101, 138, 153, and 180. Dioxin-like PCB indicates the sum of the levels of PCBs 77, 81, 114, 105, 118, 126, 123, 156, 157, 169, 167, and 189.
The effect of circulating lipid-adjusted persistent organic pollutants (natural logarithms value) on the change in metabolic components and continuous metabolic syndrome score over the 1-year follow-up, controlling for change in body mass index over time.
| Persistent Organic Pollutants | ∆ cMetS Score | Relative Change of Glucose (%) | Relative Change of HDL−c (%) | Relative Change of TG (%) | Relative Change of SBP (%) | Relative Change of DBP (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 95% CI | 95% CI | 95% CI | 95% CI | 95% CI | 95% CI | |||||||||||||
| PCB 52 | 1.91 | −0.46 | 4.29 | −0.21 | −2.74 | 2.33 | 2.66 | 0.05 | 5.26 | 0.45 | −1.42 | 2.32 | 2.05 | −0.55 | 4.65 | |||
| PCB 101 | 0.40 | −0.03 | 0.82 | −0.13 | −2.46 | 2.19 | 0.09 | −2.36 | 2.54 | 1.52 | −1.03 | 4.07 | 0.09 | −1.72 | 1.90 | 0.86 | −1.68 | 3.40 |
| PCB 118 | 0.56 | −0.08 | 1.20 | 1.06 | −2.45 | 4.56 | 0.20 | −3.50 | 3.91 | 2.01 | −1.84 | 5.86 | 0.15 | −2.58 | 2.89 | 2.93 | −0.87 | 6.74 |
| PCB 138 | 0.31 | −0.17 | 0.80 | −0.50 | −3.13 | 2.12 | −0.08 | −2.85 | 2.70 | 0.59 | −2.30 | 3.48 | 0.71 | −1.32 | 2.75 | |||
| PCB 153 | 0.14 | −0.23 | 0.50 | 0.21 | −1.76 | 2.18 | 0.86 | −1.21 | 2.93 | 0.14 | −2.03 | 2.31 | 0.95 | −0.57 | 2.48 | |||
| PCB 156 | 0.22 | −0.31 | 0.76 | −1.77 | −4.64 | 1.11 | −1.90 | −4.93 | 1.14 | 0.63 | −2.55 | 3.82 | 1.43 | −0.80 | 3.67 | 2.76 | 0.35 | 5.88 |
| PCB 180 | 0.25 | −0.14 | 0.63 | 1.03 | −1.04 | 3.10 | −0.52 | −2.71 | 1.67 | 1.35 | −0.93 | 3.63 | 1.36 | −0.25 | 2.97 | 2.05 | −0.20 | 4.30 |
| ΣPCB | 0.60 | −0.04 | 1.24 | −0.58 | −4.02 | 2.85 | −0.84 | −4.55 | 2.87 | 3.66 | −0.15 | 7.47 | 1.22 | −1.49 | 3.93 | |||
| Marker PCB | 0.51 | −0.11 | 1.12 | −0.81 | −4.10 | 2.49 | −0.34 | −3.91 | 3.22 | 1.54 | −1.06 | 4.15 | ||||||
| Dioxin-like PCB | 0.09 | −0.50 | 0.68 | −2.24 | −5.39 | 0.91 | −0.49 | −3.91 | 2.93 | 0.72 | −2.81 | 4.25 | 0.72 | −1.78 | 3.23 | 3.01 | −0.46 | 6.48 |
| HCB | 0.13 | −0.10 | 0.36 | −1.22 | −2.46 | 0.01 | 0.49 | −0.83 | 1.81 | 1.09 | −0.27 | 2.46 | 0.18 | −0.80 | 1.15 | 0.49 | −0.88 | 1.85 |
| −0.09 | −0.61 | 0.43 | −0.84 | −3.65 | 1.96 | 1.25 | −1.71 | 4.20 | 0.19 | −2.90 | 3.28 | −0.26 | −2.43 | 1.91 | 1.83 | −1.20 | 4.86 | |
| β-HCH | −0.13 | −0.45 | 0.19 | 0.65 | −1.10 | 2.39 | −1.13 | −3.05 | 0.79 | 0.20 | −1.16 | 1.57 | 1.05 | −0.86 | 2.95 | |||
| 0.03 | −0.58 | 0.64 | 1.28 | −1.99 | 4.56 | 2.11 | −1.34 | 5.56 | −0.31 | −3.93 | 3.30 | −0.15 | −2.72 | 2.41 | 1.70 | −1.89 | 5.28 | |
| −0.01 | −0.40 | 0.37 | 0.94 | −1.14 | 3.01 | 2.03 | −0.15 | 4.20 | −0.88 | −3.17 | 1.41 | 0.30 | −1.31 | 1.92 | 1.61 | −0.64 | 3.87 | |
a p < 0.05; cMetS, continuous metabolic syndrome; BMI, body mass index; HDL-c, high-density lipoprotein cholesterol; TG, triglyceride; SBP, systolic blood pressure; DBP, diastolic blood pressure; PCB, polychlorinated biphenyl; HCB, hexachlorobenzene; β-HCH, β-hexachlorocyclohexane; p,p’-DDT, p,p’-dichlorodiphenyltrichloroethane; p,p’-DDE, p,p’-dichlorodiphenyldichloroethylene. Results below the limit of detection (LOD) were imputed using the equation: LOD/√2. Multiple regression models are adjusted for sex, age (months), household income, and change in body mass index over time. Relative change (%) in the metabolic components was calculated as: (values at follow-up − values at baseline)/values at baseline × 100. Continuous metabolic syndrome (cMetS) score was evaluated as difference (∆) over time. ΣPCB indicates the sum of the levels of all 32 PCB congeners. Marker PCB indicates the sum of the levels of PCBs 28, 52, 101, 138, 153, and 180. Dioxin-like PCB indicates the sum of the levels of PCBs 77, 81, 114, 105, 118, 126, 123, 156, 157, 169, 167, and 189.